🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Found 29 matching trials

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

PHASE1

This multicenter, open-label, Phase I study will evaluate the safety, effic...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2015-07-22

Trial ID

NCT02431208

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Daratumumab Lenalidomide Pomalidomide Dexamethasone

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

PHASE1

This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-ex...

Status

Completed

Location

UCLA

Start Date

2012-08-13

Trial ID

NCT01656642

Treatments Being Tested

Atezolizumab Cobimetinib Vemurafenib

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

PHASE3

This randomized, open-label study will evaluate the safety and efficacy of ...

Status

Completed

Location

Ironwood Cancer & Research Centers

Start Date

2015-06-11

Trial ID

NCT02367794

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody Carboplatin Nab-Paclitaxel Paclitaxel

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

PHASE3

This multi-center, randomized, open-label study will evaluate the efficacy ...

Status

Completed

Location

University of Arizona Cancer Center

Start Date

2015-05-20

Trial ID

NCT02420821

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Bevacizumab Sunitinib

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

PHASE3

This is a randomized, double-blinded study designed to evaluate the efficac...

Status

Completed

Location

Arizona Oncology

Start Date

2018-04-24

Trial ID

NCT03456063

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Placebo Comparator Nab-paclitaxel Pemetrexed Carboplatin Cisplatin Gemcitabine

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

PHASE2

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluat...

Status

Unknown

Location

Ironwood Cancer and Research Center

Start Date

2019-12-17

Trial ID

NCT03961698

Treatments Being Tested

IPI-549 (eganelisib)Atezolizumab nab-paclitaxel Bevacizumab

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

PHASE3

This is a Phase III, multicenter, open-label, three-arm, randomized study i...

Status

Completed

Location

City of Hope Comprehensive Cancer Center

Start Date

2016-07-05

Trial ID

NCT02788279

Treatments Being Tested

Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody Cobimetinib Regorafenib

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

PHASE3

This global, multicenter, open-label, randomized, controlled study evaluate...

Status

Completed

Location

Comprehensive Blood/Cancer Ctr

Start Date

2014-03-11

Trial ID

NCT02008227

Treatments Being Tested

Atezolizumab Docetaxel

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

PHASE2

This is an open-label, multicenter, basket trial Phase II study to evaluate...

Status

Terminated

Location

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Start Date

2018-02-19

Trial ID

NCT03386721

Treatments Being Tested

simlukafusp alfa Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody Gemcitabine Vinorelbine

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

PHASE3

This randomized, open-label study will evaluate the efficacy and safety of ...

Status

Completed

Location

University of California San Diego

Start Date

2015-07-20

Trial ID

NCT02409342

Treatments Being Tested

Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody Carboplatin Cisplatin Gemcitabine Pemetrexed

Previous Next